HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine

Expert Opinion on Biological Therapy

Volumn 16, Issue 7, 2016, Pages 953-966

  Graziani, Gina M ^a   Angel, Jonathan B ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

AIDS; clinical trials; HIV; HIV 1 Immunogen; inactivated whole virus particles; Remune ; therapeutic vaccine

Indexed keywords

DIDANOSINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; REMUNEX IR 103; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; HIV-1 IMMUNOGEN, INCOMPLETE FREUND'S ADJUVANT;

ANTIGEN SPECIFICITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DISEASE COURSE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GENE DOSAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION SITE PAIN; INJECTION SITE RASH; MACULOPAPULAR RASH; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICENTER STUDY (TOPIC); PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INTERRUPTION; VACCINATION; VIRUS PARTICLE; VIRUS PURIFICATION; VIRUS REPLICATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; PROCEDURES;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY;

EID: 84975231585     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1193594     Document Type: Article

References (59)

1. World Health Organization. HIV/AIDS fact sheet no. 360; 2015 [cited 2015 Oct13]. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/]
2. U.S. Department of Health & Human Services. The global HIV/AIDS epidemic; global statistics; 2014 [cited 2015 Oct13]. Available from: http://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/
3. World Health Organization. 10 Facts on HIV/AIDS; 2015 [cited 2015 Oct13]. Available from: http://www.who.int/features/factfiles/hiv/facts/en/index5.html
4. S.G.Deeks, S.R.Lewin, D.V.Havlir The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525–1533.
5. S.Vella, B.Schwartlander, S.P.Sow, et al. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;26:1231–1241.
6. S.G.Deeks, B.Autran, B.Berkhout, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12:607–614.
7. The International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure; full recommendations. 1st ed; 2012 [cited 2015 Oct13]. Available from: http://www.iasociety.org/Web/WebContent/File/HIV_Cure_Full_recommendations_July_2012.pdf
8. G.Vanham, G.E.Van. Can immunotherapy be useful as a “functional cure” for infection with human immunodeficiency virus-1? Retrovirology. 2012;9:72.
9. B.Joos, M.Fischer, H.Kuster, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008;105:16725–16730.
10. Adis International Ltd. HIV vaccine–immune response. AG 1661. IR-8101, IR8101, Remune, RG 83894. Drugs R D. 2002;3:411–420.
11. J.Salk. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 1987;327:473–476.
12. PR Newswire. The Immune Response Corporation granted patent in South Africa for novel formulation of Remune(R); 2002 [cited 2015 Oct13]. Available from: http://www.prnewswire.com/news-releases/the-immune-response-corporation-granted-patent-in-south-africa-for-novel-formulation-of-remuner-77214627.html
13. Immune Response BioPharma, Inc. About Immune Response BioPharma, Inc. FAQ; 2014 [cited 2015 Oct13]. Available from: http://www.immuneresponsebiopharma.com/Pages/aboutus.aspx
14. A.M.Levine, S.Groshen, J.Allen, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:351–364.
15. S.Kinloch-de Loes, B.Hoen, D.E.Smith, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis. 2005;192:607–617.
16. National Institute of Allergy and Infectious Diseases (NIAID). A phase III, randomized, double-blind, placebo-controlled evaluation of the effect of immunization with an HIV immunogen on the time to virologic relapse in individuals receiving potent, suppressive antiretroviral therapies; 2012 [cited 2015 Oct13]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00005758
17. Evaluate™. The Immune Response Corporation licenses Hybridon’s 2nd generation CpG DNA adjuvant, AMPLIVAX(TM), for use in development of a novel vaccine for the prevention and treatment of HIV; 2003 [cited 2015 Oct13]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=133958
18. Immune Response BioPharma, Inc. Remune + Amplivax IR103 HIV/AIDS phase III safety & efficacy study; 2015 [cited 2015 Oct13]. Available from: www.clinicaltrials.gov/ct2/show/NCT02366026
19. V.Churdboonchart, C.Sakondhavat, S.Kulpradist, et al. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of >300. Clin Diagn Lab Immunol. 2000;7:728–733.•• Immunization with HIV-1 immunogen improved CD4 T-cell count and percentage and CD4/CD8 ratio (phase 2 P2101B study).
20. Remune vaccine. Immune Response BioPharma, Inc. 2015 [cited 2015 Oct13]. Available from: http://www.immuneresponsebiopharma.com/Pages/REMUNEVaccine.aspx
21. S.P.Richieri, R.Bartholomew, R.C.Aloia, et al. Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine. 1998;16:119–129.
22. D.J.Choi, S.Dube, T.P.Spicer, et al. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses. 1997;13:357–361.
23. R.J.Trauger, F.Ferre, A.E.Daigle, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis. 1994;169:1256–1264.
24. R.B.Moss, F.Ferre, A.Levine, et al. Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy. J Clin Immunol. 1996;16:266–271.
25. A.Limsuwan, V.Churdboonchart, R.B.Moss, et al. Safety and immunogenicity of Remune in HIV-infected Thai subjects. Vaccine. 1998;16:142–149.
26. V.Churdboonchart, R.B.Moss, W.Sirawaraporn, et al. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS. 1998;12:1521–1527.
27. B.K.Patterson, D.J.Carlo, M.H.Kaplan, et al. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS. 1999;13:1607–1611.
28. G.A.Hardy, N.Imami, M.R.Nelson, et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccines. 2007;5:6.
29. J.Pido-Lopez, C.Burton, G.Hardy, et al. Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune). AIDS Res Hum Retroviruses. 2003;19:103–109.
30. R.B.Moss, C.Brandt, W.K.Giermakowska, et al. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine. 2003;21:1066–1071.
31. K.H.Huang, M.P.Boisvert, F.Chung, et al. Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption. J Immune Based Ther Vaccines. 2006;4:7.
32. S.Sei, S.L.Sandelli, G.Theofan, et al. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis. 1999;180:626–640.
33. J.B.Angel, J.P.Routy, C.Tremblay, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS. 2011;25:731–739.
34. C.T.Costiniuk, C.Kovacs, J.P.Routy, et al. Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res Hum Retroviruses. 2013;29:266–269.
35. W.Sukeepaisarncharoen, V.Churdboonchart, S.Kulpradist, et al. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy. HIV Clin Trials. 2001;2:391–398.
36. W.Chantratita, W.Sukeepaisarncharoen, V.Chandeying, et al. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (Remune) therapy in Thailand. HIV Med. 2004;5:317–325.
37. G.K.Robbins, M.M.Addo, H.Troung, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 2003;17:1121–1126.
38. E.Fernandez-Cruz, S.Moreno, J.Navarro, et al. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine. 2004;22:2966–2973.•• Immunization with HIV-1 immunogen resulted in a trend toward delayed viral rebound (phase 2 STIR-2101 study).
39. L.Valor, J.Navarro, J.Carbone, et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine. 2008;26:2738–2745.
40. R.B.Moss, F.Ferre, R.Trauger, et al. Inactivated HIV-1 Immunogen: impact on markers of disease progression. J Acquir Immune Defic Syndr. 1994;7(Suppl 1):S21–S27.•• Immunization with HIV-1 immunogen significantly reduced viral load and decline in CD4 T cell percentage (phase 2/3 study).
41. R.J.Trauger, A.E.Daigle, W.Giermakowska, et al. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(Suppl 2):S74–S82.
42. 6/L CD4 cell counts: a randomized controlled trial. JAMA. 2000;284:2193–2197.•• Describes the terminated phase 3 trial that concluded that immunization with HIV-1 Immunogen did not confer any clinical benefits.
43. The Immune Response Corporation. A multicenter, double-blind, phase III, adjuvant-controlled study of the effect of 10 units of HIV-1 Immunogen (Remune) compared to Incomplete Freund’s Adjuvant (IFA) alone every 12 weeks on AIDS-free survival in subjects with HIV infection and CD4 T-lymphocytes between 300 and 549 cells/microL regardless of concomitant HIV therapies; 2005 [cited 2015 Oct13]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00002359
44. J.L.Turner, J.R.Kostman, A.Aquino, et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med. 2001;2:68–77.•• HIV-1 immunogen significantly decreased viral load and tended to increase CD4 T cell count in a substudy of the phase 3 trial reported by Kahn et al. [42].
45. J.O.Kahn, S.Lagakos. Letters. Outcomes of a trial of HIV-1 Immunogen in patients with HIV infection (in reply). JAMA. 2001;285:2191–2195.• This paper addresses the controversies and legal actions associated with the publication of the terminated phase 3 clinical trial.
46. D.Glidden, S.Kim, S.Lagakos. Effectiveness of Remune. Clin Diagn Lab Immunol. 2001;8:468–469.• A co-investigator critique of the statistical analysis used by Churdboonchart et al. [19] in the phase 2 P2101B study.
47. P.Lurie, S.M.Wolfe. Letters. Outcomes of a trial of HIV-1 immunogen in patients with HIV infection. JAMA. 2001;285:2193–2195.• This paper discusses protocol violations that occurred in the Trauger et al. [23] phase 2/3 study that resulted in the issue of an FDA warning letter to the study sponsor.
48. Editorial. Collaborative conflicts. Nat Immunol. 2000;1:449.
49. C.C.Morton. Clinical trials. Company, researchers battle over data access. Science. 2000;290:1063.
50. Immune Response BioPharma, Inc files BLA with the FDA for Remune HIV/AIDS vaccine marketing approval [Press Release]. Immune Response BioPharma. 2014 [cited 2016 Jan19]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=550140
51. Immune Response BioPharma, Inc. announces Remune FDA BLA assignment PDUFA goal December 22nd 2015 [Press Release] [Internet]. Immune Response BioPharma. 2015 [cited 2016 Jun1]. Available from: http://www.biospace.com/news_story.aspx?StoryID=364821
52. Immune Response BioPharma, Inc. Provides Remune BLA FDA filing update [Press Release]. Immune Response BioPharma [Internet]. 2015 [cited 2016 Jun1]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=567945
53. Immune Response BioPharma, Inc. announces the FDA has accepted Remune HIV/AIDS vaccine BLA for review [Press Release] [Internet]. Immune Response BioPharma. 2015 [cited 2016 Jan19]. Available from: https://www.evaluategroup.com/Universal/View.aspx?type=Story&id=567944
54. U.S. Food and Drug Administration. Remune orphan drug designation [Internet]. 2014 [cited 2016 Jun1]. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=420113
55. Immune Response BioPharma, Inc. Remune HIV/AIDS vaccine Phase II pediatric safety & efficacy clinical study; 2015 [cited 2015 Oct13]. Available from: http://clinicaltrials.gov/ct2/show/NCT02291809
56. J.L.Anderson, R.Fromentin, G.M.Corbelli, et al. Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium. AIDS Res Hum Retroviruses. 2015;31:36–44.
57. J.Thornhill, S.Fidler, J.Frater. Advancing the HIV cure agenda: the next 5 years. Curr Opin Infect Dis. 2015;28:1–9.
58. Western University. HIV/AIDS vaccine developed at the University of Western Ontario proceeding to human clinical trials [Internet]. 2011 [cited 2015 Oct13]. Available from: www.schulich.uwo.ca/schulichhome/articles/2011/12/20/hiv-aids-vaccine-developed-at-the-university-of-western-ontario-proceeding-to-human-clinical-trials
59. Immune Response BioPharma, Inc. receives FDA Complete Response Letter for Remune HIV vaccine [Press Release] [Internet]. Immune Response BioPharma. 2015 [cited 2016 May31]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=623610